Callan Capital LLC Acquires Shares of 6,726 IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Callan Capital LLC acquired a new stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 6,726 shares of the company’s stock, valued at approximately $239,000.

Other hedge funds have also recently modified their holdings of the company. Federated Hermes Inc. lifted its stake in shares of IDEAYA Biosciences by 14.8% in the fourth quarter. Federated Hermes Inc. now owns 3,883,775 shares of the company’s stock worth $138,185,000 after buying an additional 500,046 shares in the last quarter. Walleye Capital LLC bought a new position in IDEAYA Biosciences during the third quarter valued at approximately $2,265,000. Boone Capital Management LLC lifted its position in IDEAYA Biosciences by 15.0% during the third quarter. Boone Capital Management LLC now owns 570,682 shares of the company’s stock valued at $15,397,000 after purchasing an additional 74,249 shares during the period. Barclays PLC lifted its position in IDEAYA Biosciences by 17.8% during the third quarter. Barclays PLC now owns 86,326 shares of the company’s stock valued at $2,330,000 after purchasing an additional 13,049 shares during the period. Finally, Eventide Asset Management LLC bought a new position in IDEAYA Biosciences during the third quarter valued at approximately $9,038,000. Hedge funds and other institutional investors own 98.29% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on IDYA shares. Capital One Financial restated an “overweight” rating on shares of IDEAYA Biosciences in a research report on Thursday, February 22nd. Royal Bank of Canada upped their target price on shares of IDEAYA Biosciences from $43.00 to $53.00 and gave the company an “outperform” rating in a report on Wednesday, February 21st. Citigroup upped their target price on shares of IDEAYA Biosciences from $40.00 to $60.00 and gave the company a “buy” rating in a report on Thursday, March 21st. BTIG Research began coverage on shares of IDEAYA Biosciences in a report on Friday, March 8th. They set a “buy” rating and a $55.00 target price for the company. Finally, JPMorgan Chase & Co. upped their target price on shares of IDEAYA Biosciences from $51.00 to $57.00 and gave the company an “overweight” rating in a report on Friday, February 23rd. Twelve analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, IDEAYA Biosciences presently has a consensus rating of “Buy” and a consensus target price of $46.60.

IDEAYA Biosciences Trading Up 3.4 %

IDYA traded up $1.32 during trading on Friday, hitting $39.94. 619,378 shares of the company traded hands, compared to its average volume of 852,284. The company has a market cap of $2.99 billion, a PE ratio of -20.27 and a beta of 0.80. The stock’s 50-day simple moving average is $43.14 and its two-hundred day simple moving average is $37.46. IDEAYA Biosciences, Inc. has a 1 year low of $18.11 and a 1 year high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its earnings results on Tuesday, February 20th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.05). The company had revenue of $3.90 million for the quarter, compared to analysts’ expectations of $8.84 million. IDEAYA Biosciences had a negative net margin of 483.05% and a negative return on equity of 23.00%. The firm’s revenue for the quarter was down 3.0% compared to the same quarter last year. Equities analysts expect that IDEAYA Biosciences, Inc. will post -2.26 EPS for the current year.

Insider Activity at IDEAYA Biosciences

In other IDEAYA Biosciences news, insider Briseno Andres Ruiz sold 2,000 shares of the stock in a transaction on Friday, February 9th. The shares were sold at an average price of $46.02, for a total transaction of $92,040.00. Following the completion of the transaction, the insider now owns 24,531 shares in the company, valued at $1,128,916.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other IDEAYA Biosciences news, insider Briseno Andres Ruiz sold 2,000 shares of the stock in a transaction on Friday, February 9th. The shares were sold at an average price of $46.02, for a total transaction of $92,040.00. Following the completion of the transaction, the insider now owns 24,531 shares in the company, valued at $1,128,916.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Yujiro S. Hata sold 23,557 shares of the firm’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $45.54, for a total transaction of $1,072,785.78. Following the completion of the sale, the chief executive officer now owns 677,887 shares of the company’s stock, valued at approximately $30,870,973.98. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by corporate insiders.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.